Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LVGN6051 + toripalimab + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Lijin Biomedical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
LVGN6051 + toripalimab + paclitaxel is a combination regimen of three agents: LVGN6051 (an agonistic monoclonal antibody targeting 4-1BB, designed to activate T cells in the tumor microenvironment), toripalimab (a PD-1 immune checkpoint inhibitor monoclonal antibody), and paclitaxel (a chemotherapeutic agent in the taxane class that stabilizes microtubules to prevent mitosis). This combination is under investigation for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The rationale is to combine T cell activation (4-1BB agonist), immune checkpoint blockade (PD-1 inhibitor), and cytotoxic chemotherapy to synergistically enhance antitumor immunity and directly kill tumor cells. LVGN6051 is being developed by Lyvgen; toripalimab is developed by Junshi Biosciences; paclitaxel is a widely marketed cytotoxic agent.
- Other names
- paclitaxeltoripalimabLVGN6051LVGN-6051LVGN 6051
02
Targets
TNFRSF9 (CD137 extracellular domain)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LVGN6051 + toripalimab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LVGN6051 + toripalimab + paclitaxel.